HEADLINES: • Hungary macro: MNB on hold • Cyfrowy Polsat: TiVi Foundation exercises its rights to replace the managers and a supervisory board member of the group POSITIVE • Medicover: 2Q25 results preview (due out tomorrow) • Tofas: 2Q25 earnings preview (due on 28 July) • Ford Otosan: 2Q25 earnings preview (due on 30 July) • Teknosa: 2Q25 earnings preview (due on 6 August) • Short News (EUR, 4iG, PPC)
HEADLINES: • EMEA Airlines: 2Q25 traffic - Easter good, conflict bad • GEK Terna: motorway traffic grows faster than expected in 1H25 POSITIVE • Benefit Systems: changes in the Supervisory Board NEUTRAL • Allegro: expands its delivery network via a partnership with Zabka, adding 11,600+ new pick-up points NEUTRAL • Jahez: takeaways from the conference call on the Snoonu deal POSITIVE • Titan Cement: 2Q25E financial results preview (due on 31 July)
Calendar 2Q25 started off well for the sector, benefitting from the Easter effect and low fuel prices, but many airlines experienced disruptions to their networks later in the quarter, following Israel’s attack on Iran. Demand for flying seems broadly resilient so far, with fares helped by limited capacity growth in Europe, due to supply constraints. As we move into the peak season, Air Traffic Control (ATC) remains a bottleneck, especially as parts of the European network remain closed to traff...
MedLife is an integrated provider of healthcare services in Romania able to accompany the patient across the entire medical journey from prevention to diagnosis to treatments in clinics and hospitals. We expect the company to continue to capitalise on the growth of private healthcare spending in Romania. The current valuation of 9.5x 2026e EV/EBITDA is in line with its peers, while we project EBITDA growth of 16% p.a. until 2027e compared to high single digit growth for peers. We are therefore i...
HEADLINES: • EME Macro/Strategy: macro all-in-one (14-20 July) • OPAP: acquires remaining 15.5% stake in Stoiximan POSITIVE • Solutions by STC: 2Q25E financial results preview (due out tomorrow) • Borouge: 2Q25E results preview (due on 31 July) NEUTRAL • Grupa Pracuj: 2Q25E results preview – 3% yoy adjusted EBITDA growth expected (due on 28 August) • Erste Bank: 2Q25E preview (due on 1 August) • OTP Bank: 2Q25E preview (due on 5 August) • Bank Pekao: 2Q25E preview (due on 7 August) • PKO BP: 2Q2...
HEADLINES: • Ukraine macro: notes on the economy and the reconstruction process • VIGO Photonics: 2Q25 sales down 11% yoy, to PLN 20.3m NEGATIVE • Mo-BRUK: refund of interest on the overpayment related to the 2017 waste disposal decision NEUTRAL • CD Projekt: Cyberpunk to be released for Apple Macs tomorrow NEUTRAL • Sipchem: 2Q25E results preview (due on 21 July) NEUTRAL • Budimex: 2Q25E preview – EBIT up slightly, by 5% yoy (prelims due on 28 July) • Tupras: 2Q25E results preview (due on 29 Ju...
HEADLINES: • Aselsan: to tap DIRCM market POSITIVE • Romania macro: Government survives vote of no confidence, as expected • Wizz Air: to exit Abu Dhabi by the end of the summer • Bank Pekao: to book PLN 417m of extra provisions related to various legal risks in 2Q25E NEUTRAL • Grupa Pracuj: new job ads on Pracuj.pl at 395,000 in 1H25, flat yoy NEUTRAL • Lamda Development: completes early repayment of EUR 230m retail bond NEUTRAL • MONETA Money Bank: 2Q25E preview (due on 24 July) • Bank Millenn...
HEADLINES: • EME Macro/Strategy: macro all-in-one (7-13 July) • EU macro: US tariff announcement worse than expected • PKO BP: to book PLN 1.25bn of FX mortgage saga costs in 2Q25E NEUTRAL • Metlen Energy & Metals: MSCI to keep the stock in the Greece Standard index, as largely expected • Wirtualna Polska: 2Q25E preview – soft quarter, with 1% yoy pro-forma adjusted EBITDA growth expected (due on 26 August)
HEADLINES: • TBC Bank: good run, approaching fair value (downgraded to HOLD) • Krka: preliminary 2Q25 numbers – a mixed bag NEUTRAL • GEK Terna: 50/50 JV with Motor Oil Hellas over their electricity supply and gas-fired power generation activities POSITIVE • DO & CO: EUR 2.00/share dividend approved, in line with our estimate NEUTRAL • OTE: 2Q25E results preview – 2% yoy adjusted EBITDA growth expected (due on 6 August)
A director at Med Life SA sold 2,000,000 shares at 6.750RON and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.